1. High-value consumables are bidding farewell to their high gross margins. Following the National Development and Reform Commission’s 2017 negotiations for three categories of high-value consumables, prices plummeted. And these three are by no means the only ones; additional national-level price‑negotiation rounds for more high-value consumables are expected in 2018, using price reductions to secure larger market volumes—a strategy that may well benefit companies, as survival remains the top priority at this stage.

　　In addition, hospitals are set to implement a zero‑markup policy for medical consumables. With zero markup in place, pricing is no longer tied to the hospital’s profit margin—so why should they sell at inflated prices? Higher prices also drive up the consumables‑to‑total‑cost ratio; if that ratio gets out of control, even hospital presidents and department heads could face dismissal. Moving away from high‑margin pricing has become inevitable.

　　2. The four major departments are gradually being spun off. Following 2018, the radiology, laboratory, pathology, and hemodialysis departments will undergo a phased separation process. According to medical planning documents from numerous prefecture-level cities spanning 2017–2020, many of these plans explicitly call for the establishment of regional imaging, laboratory, pathology, and hemodialysis centers, with subsequent implementation of shared-use arrangements. Consequently, the gradual divestiture of these key departments is expected to follow. However, given that new facilities still need to be built or renovated, substantial momentum or large-scale moves in this direction are unlikely until such infrastructure is fully in place.

　　In addition, five major centers—rehabilitation, nursing, sterilization and supply, small- and medium-sized ophthalmology, and health check-ups—will also be gradually spun off.

　　3. A brutal price war is raging in China’s medical imaging sector. Although technological progress has finally begun to emerge, the market has already shifted from blue to red, with price wars intensifying over the past two years—and they show no signs of abating in 2018. Yuwell, Wandong, and Alibaba have jointly acquired Baisheng Medical for nearly RMB 2 billion; United Imaging secured RMB 3.33 billion in funding, while Conda raised RMB 1 billion; meanwhile, Tencent’s Miiying has also entered the fray. This field boasts numerous strong players and ample capital, yet the market remains limited. Even before capturing much ground from the established GPS trio—GE, Philips, and Siemens—China’s domestic manufacturers are already locked in a fierce elimination round.

　　4. Exponential cross‑industry expansion has emerged as a new trend. Following the “Healthy China 2030” plan, a series of supporting policies have been rolled out, including the state’s vigorous promotion of health‑oriented sports, health tourism, integrated medical‑and‑elderly‑care services, and the rehabilitation sector, as well as the strong push by private capital for the medical‑aesthetic industry. All these developments are poised to create substantial market opportunities for the medical device industry and its enterprises.

　　These are broad, expansive, and cross‑industry domains that are closely linked to medical devices. Many companies observe that, at present, these sectors still lack dominant industry leaders and well‑established branded products. The hospital market is worth several billion, while the non‑hospital market amounts to another several billion; perhaps even more promising is the broader market beyond hospitals—truly a vast and untapped frontier.

　　5. Marketing is entering a period of transformation. When it comes to the “marketing game” for consumables and reagents in hospitals, there’s little new to report; under stricter oversight, it’s becoming increasingly difficult to secure meetings with department heads or hospital administrators, and the associated risks are mounting. Meanwhile, the practice of “bidding‑room lobbying” in equipment procurement has not diminished simply because a year has passed—on the surface, little seems to have changed.

　　The real impact lies in the fact that, under the healthcare reform and its accompanying policies, companies’ profit margins have narrowed, while hidden costs have remained unchanged. The two‑invoice system has also directly disrupted firms’ traditional marketing models; many hospitals have been placed under trusteeship, and numerous laboratory departments have been partially outsourced to private entities—so is there still a market for you? Marketing transformation is no longer just talk; the time for change has truly arrived. Without new breakthroughs, the only outcome will be stagnation—or worse.

　　6. More companies are seeking to tap into international markets. At this year’s MEDICA trade fair in Düsseldorf, Germany, Chinese enterprises fielded a sizable delegation, underscoring the widespread drive to break through in global markets. Meanwhile, the domestic market is grappling with tightening industry regulations, a complex regulatory landscape, formidable competitors, and shrinking profit margins—challenges that have made doing business increasingly difficult. As a result, many medical device firms are turning their attention to overseas expansion, particularly in developing markets, where they are achieving notable success.

　　7. The wave of entrepreneurship and venture capital financing remains robust. In 2017, which is drawing to a close, the medical device sector likely saw the highest number of startups, innovations, and investment deals—largely because the industry is still in its early growth phase, offering abundant opportunities. By contrast, the pharmaceutical sector has entered a consolidation phase: while investment funds are eager to enter the broader health‑care space, identifying high‑quality drug‑development projects has become exceedingly difficult, leaving mergers and acquisitions as the only viable avenue for pharmaceuticals.

　　Medical device innovation is relatively easier, and the market offers substantial growth potential, prompting funds to prioritize this sector. It is foreseeable that the wave of entrepreneurship, innovation, and investment in the medical device industry will continue in 2018. Moreover, among the companies that secured funding over the past one or two years, a number are expected to go public throughout 2018.

　　8. Medical AI is on the verge of becoming ubiquitous. In the healthcare sector, aside from a handful of genuine players actively pursuing this field, most of the attention comes from publicly listed companies touting the concept—whose motives are self‑evident. The idea has become extremely popular, and there are numerous opportunities for integration within the medical and medical‑device industries, with a sufficiently large market size. By 2018, the trend may shift from hype to oversaturation.